ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2015
Estimating the potential effects of a vaccine program against an emerging influenza pandemic--United States.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Virus-induced pathogenesis, vaccine development, and diagnosis of novel H7N9 avian influenza A virus in humans: a systemic literature review.The Journal of international medical research · 2020Pooled it
- Article
- Multi-period vaccine allocation model in a pandemic: A case study of COVID-19 in Australia.Transportation research. Part E, Logistics and transportation review · 2022Article
- Article
- A Framework for Discovering Health Disparities among Cohorts in an Influenza Epidemic.World wide web · 2019Article
- Article
- Influenza illness averted by influenza vaccination among school year children in Beijing, 2013-2016.Influenza and other respiratory viruses · 2018Article
- Assessing the benefits of early pandemic influenza vaccine availability: a case study for Ontario, Canada.Scientific reports · 2018Article
- Low coverage rate and awareness of influenza vaccine among older people in Shanghai, China: A cross-sectional study.Human vaccines & immunotherapeutics · 2018Article
- Epidemiological and economic impact of pandemic influenza in Chicago: Priorities for vaccine interventions.PLoS computational biology · 2017Article
- Pandemic Risk Assessment Model (PRAM): a mathematical modeling approach to pandemic influenza planning.Epidemiology and infection · 2016Article
- Integrating pharmacies into public health program planning for pandemic influenza vaccine response.Vaccine · 2016Article
- Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis.Antimicrobial agents and chemotherapy · 2016Article
- Infant Respiratory Outcomes Associated with Prenatal Exposure to Maternal 2009 A/H1N1 Influenza Vaccination.PloS one · 2016Article
- Standardizing scenarios to assess the need to respond to an influenza pandemic.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHuman illness from influenza A(H7N9) was identified in March 2013, and candidate vaccine viruses were soon developed. To understand factors that may impact influenza vaccination programs, we developed a model to evaluate hospitalizations and deaths averted considering various scenarios.
methodsWe utilized a model incorporating epidemic curves with clinical attack rates of 20% or 30% in a single wave of illness, case hospitalization ratios of 0.5% or 4.2%, and case fatality ratios of 0.08% or 0.53%. We considered scenarios that achieved 80% vaccination coverage, various starts of vaccination programs (16 or 8 weeks before, the same week of, or 8 or 16 weeks after start of pandemic), an administration rate of 10 or 30 million doses per week (the latter rate is an untested assumption), and 2 levels of vaccine effectiveness (2 doses of vaccine required; either 62% or 80% effective for persons aged <60 years, and either 43% or 60% effective for persons aged ≥ 60 years).
resultsThe start date of vaccination campaigns most influenced impact; 141,000-2,200,000 hospitalizations and 11,000-281,000 deaths were averted when campaigns started before a pandemic, and <100-1 300,000 hospitalizations and 0-165,000 deaths were averted for programs beginning the same time as or after the introduction of the pandemic virus. The rate of vaccine administration and vaccine effectiveness did not influence campaign impact as much as timing of the start of campaign.
conclusionsOur findings suggest that efforts to improve the timeliness of vaccine production will provide the greatest impacts for future pandemic vaccination programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.